Key Points
- CEO Massimo Calafiore sold 9,797 shares on Jan. 12 at an average $15.21 (≈$149,012), after selling 9,600 shares on Jan. 9 at $15.82; following the Jan. 12 sale he directly owns 217,237 shares (~$3.3M), a 4.32% reduction in his stake.
- Orthofix shares opened at $14.81 and trade in a 12‑month range of $10.24–$20.48, while analysts have an average rating of "Moderate Buy" with a consensus target price of $21.50.
- Institutional investors own 89.76% of the stock, with notable position increases including Engine Capital raising its stake to about 4.25 million shares.
Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) CEO Massimo Calafiore sold 9,797 shares of the company's stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $15.21, for a total value of $149,012.37. Following the sale, the chief executive officer directly owned 217,237 shares of the company's stock, valued at approximately $3,304,174.77. This represents a 4.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Massimo Calafiore also recently made the following trade(s):
- On Friday, January 9th, Massimo Calafiore sold 9,600 shares of Orthofix Medical stock. The shares were sold at an average price of $15.82, for a total value of $151,872.00.
Orthofix Medical Price Performance
Orthofix Medical stock opened at $14.81 on Wednesday. Orthofix Medical Inc. has a 12 month low of $10.24 and a 12 month high of $20.48. The company has a debt-to-equity ratio of 0.39, a current ratio of 2.47 and a quick ratio of 1.38. The business has a 50 day simple moving average of $15.39 and a 200-day simple moving average of $14.26. The stock has a market capitalization of $586.48 million, a PE ratio of -4.89 and a beta of 0.79.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on OFIX. Stifel Nicolaus started coverage on shares of Orthofix Medical in a research note on Tuesday, October 28th. They issued a "buy" rating and a $22.00 target price for the company. Barrington Research lifted their price objective on Orthofix Medical from $17.00 to $18.00 and gave the company an "outperform" rating in a report on Wednesday, November 5th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Orthofix Medical in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $21.50.
Read Our Latest Stock Report on Orthofix Medical
Institutional Trading of Orthofix Medical
A number of institutional investors have recently added to or reduced their stakes in the stock. AYAL Capital Advisors Ltd increased its holdings in Orthofix Medical by 74.7% in the second quarter. AYAL Capital Advisors Ltd now owns 943,203 shares of the medical device company's stock valued at $10,517,000 after buying an additional 403,433 shares in the last quarter. Squarepoint Ops LLC grew its holdings in shares of Orthofix Medical by 515.6% in the 2nd quarter. Squarepoint Ops LLC now owns 117,666 shares of the medical device company's stock worth $1,312,000 after acquiring an additional 98,552 shares during the period. Gradient Capital Advisors LLC purchased a new position in Orthofix Medical in the 2nd quarter valued at approximately $223,000. Engine Capital Management LP raised its holdings in Orthofix Medical by 13.6% during the second quarter. Engine Capital Management LP now owns 4,251,671 shares of the medical device company's stock worth $47,406,000 after purchasing an additional 510,281 shares during the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Orthofix Medical during the second quarter worth $147,000. Hedge funds and other institutional investors own 89.76% of the company's stock.
Orthofix Medical Company Profile
(
Get Free Report)
Orthofix Medical Inc (NASDAQ: OFIX) is a global medical device company focused on the design and development of innovative orthopedic and spinal solutions. The company's core business is divided into two segments: spine and orthopedics. In the spine segment, Orthofix offers a range of titanium implants, biologics and portable bone growth stimulation devices designed to support spinal fusion, deformity correction and minimally invasive procedures. Its orthopedic segment encompasses products for fracture fixation, external fixation systems, trauma care and sports medicine, providing surgeons with implantable devices and instruments for complex bone reconstruction and healing.
Orthofix's product portfolio includes strut systems, bone growth stimulators, interbody fusion devices and fixation hardware that address various indications such as degenerative disc disease, spinal deformities, non-unions and long-bone fractures.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
